Revcovi (elapegademase-lvlr) is a new enzyme replacement therapy indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

In the last several years, global market of Elapegademase-lvlr developed rapidly, with an average growth rate of 9.14% during 2014 to 2018. In 2018, global revenue of Elapegademase-lvlr is nearly 11 M USD; the actual sales are about 1934 Unit.

This report focuses on Elapegademase-lvlr volume and value at global level, regional level and company level. From a global perspective, this report represents overall Elapegademase-lvlr market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, and Japan.

At company level, this report focuses on the sales, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Leadiant Biosciences
Orchard Therapeutics
Teijin Pharma

Segment by Regions
North America
Europe
Japan
Rest of World

Segment by Type
Revcovi
Strimvelis
Adagen

Segment by Application
Pediatric
Adult